**Supplementary Table S2. Baseline characteristics of patients included vs excluded from analysis.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Included  (n = 150)** | **Excluded  (n = 179)** | ***p* value** |
| Median age (IQR), years | 62.0 (54.0–70.0) | 66.0  (58.0–72.0) | 0.053 | |
| Sex, n (%) |  |  |  | |
| Female | 28 (18.7) | 31 (17.3) | 0.862 | |
| Male | 122 (81.3) | 148 (82.7) |  | |
| Race, n (%) |  |  |  | |
| Asian | 94 (62.7) | 92 (51.4) | 0.021 | |
| White | 42 (28.0) | 77 (43.0) |  | |
| Other | 4 (2.7) | 1 (0.6) |  | |
| Unknown | 10 (6.7) | 9 (5.0) |  | |
| Median baseline AFP (IQR), ng/ml | 1354.5  (121.0–8735.7) | 5.4  (3.1–10.7) |  | |
| ECOG PS, n (%) |  |  |  | |
| 0 | 101 (67.3) | 106 (59.2) | 0.161 | |
| 1 | 49 (32.7) | 73 (40.8) |  | |
| Child-Pugh class, n (%) |  |  |  | |
| A5 | 106 (70.7) | 130 (72.6) | 0.399 | |
| A6 | 44 (29.3) | 46 (25.7) |  | |
| B7 | 0 | 1 (0.6) |  | |
| Unknown | 0 | 2 (1.1) |  | |
| Etiology, n (%) |  |  |  | |
| HBV | 81 (54.0) | 81 (45.3) | 0.064 | |
| HCV | 34 (22.7) | 35 (19.6) |  | |
| Non-viral | 35 (23.3) | 63 (35.2) |  | |
| BCLC stage, n (%) |  |  |  | |
| A1/A4 | 5 (3.3) | 3 (1.7) | 0.141 | |
| B | 17 (11.3) | 33 (18.4) |  | |
| C | 128 (85.3) | 143 (79.9) |  | |
| Extrahepatic spread, n (%) | 101 (67.3) | 106 (59.2) | 0.161 | |
| Median time from initial diagnosis (IQR), mo | 6.0 (1.9–15.4) | 7.6 (2.2–23.0) | 0.124 | |
| Prior locoregional therapy,a  n (%) | 95 (63.3) | 139 (77.7) | 0.006 | |
| Median number of metastatic sites (IQR), n | 1.0 (0.0–1.0) | 0.0 (0.0–1.0) | 0.091 | |
| AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group performance score; IQR, interquartile range. a Includes local therapy, radiotherapy, and surgery. | | | | |